This document provides an overview of Good Manufacturing Practice (GMP) requirements for materials used in pharmaceutical manufacturing. It discusses specific requirements for different types of materials including starting materials, packaging materials, intermediates, finished products, and more. The objectives are to review GMP requirements for each material type and examine common problems associated with materials compliance. The document outlines general material controls such as supplier approval, material receipt checks, quarantine, storage conditions, labeling, and change control.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Site Master File or SMF is a document in the pharmaceutical industry which provides information about the production and control of manufacturing operations. The document is created by a manufacturer.
It's a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, the site master file need describe only those operations, e.g., analysis, packaging.
What is IPQC & IPQC Test
Appearance
Drug content determination
pH
Sensitivity test
Spreadability
Rate of absorption
Extrudability
Consistency Test
Rheology & Viscosity
In this slide contains definition, importance, benefits of annual product review.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).
RIPER, anantapur.
Training in a CGMP environment is very important as it is a very important requirement of the regulations. Training is simply one of the means to fill the gaps of performance between the actual results and the expected results.
ANALYSIS OF RAW MATERIALS, FINISHED PRODUCTS, PACKAGING MATERIALS, IPQC, CPCS...Khadeeja6
RAW MATERIALS
It is basically the chemical ingredients of a process. starting material, in production of final product.
FINISHED PRODUCTS
Marketable product, transportable pack, salable pack
PACKAGING MATERIAL
Providing presentation, protection, identification, information, containment, convenience compliance, integrity and stability for a product during storage, transportation display and until it is consumed or throughout its shelf life.
IPQC
Providing accurate, specific and definite description of the procedures to be employed from the receipt of raw materials to the release of the finished dosage form.
CPCSEA GUIDELINES
Role of CPCSEA is to monitor animal experiments through ethics committees set up in institutions (IAEC)
CPCSEA Nominee -important link between CPCSEA and IAEC
IAEC scrutinize all project proposals for experimentation on animals.
The validity of IAEC is for 3 years.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Site Master File or SMF is a document in the pharmaceutical industry which provides information about the production and control of manufacturing operations. The document is created by a manufacturer.
It's a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, the site master file need describe only those operations, e.g., analysis, packaging.
What is IPQC & IPQC Test
Appearance
Drug content determination
pH
Sensitivity test
Spreadability
Rate of absorption
Extrudability
Consistency Test
Rheology & Viscosity
In this slide contains definition, importance, benefits of annual product review.
Presented by: Ravi Sanker babu .D.V (Department of pharmaceutical analysis and quality assurance).
RIPER, anantapur.
Training in a CGMP environment is very important as it is a very important requirement of the regulations. Training is simply one of the means to fill the gaps of performance between the actual results and the expected results.
ANALYSIS OF RAW MATERIALS, FINISHED PRODUCTS, PACKAGING MATERIALS, IPQC, CPCS...Khadeeja6
RAW MATERIALS
It is basically the chemical ingredients of a process. starting material, in production of final product.
FINISHED PRODUCTS
Marketable product, transportable pack, salable pack
PACKAGING MATERIAL
Providing presentation, protection, identification, information, containment, convenience compliance, integrity and stability for a product during storage, transportation display and until it is consumed or throughout its shelf life.
IPQC
Providing accurate, specific and definite description of the procedures to be employed from the receipt of raw materials to the release of the finished dosage form.
CPCSEA GUIDELINES
Role of CPCSEA is to monitor animal experiments through ethics committees set up in institutions (IAEC)
CPCSEA Nominee -important link between CPCSEA and IAEC
IAEC scrutinize all project proposals for experimentation on animals.
The validity of IAEC is for 3 years.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Quy trình kiểm soát thay đổi sau khi cấp Giấy chứng nhận GMP/Giấy chứng nhận đủ điều kiện kinh doanh dược đối với cơ sở sản xuất thuốc, nguyên liệu làm thuốc
Quy trình đánh giá đáp ứng “Thực hành tốt sản xuất thuốc, nguyên liệu làm thuốc” (GMP) đối với cơ sở không thuộc diện cấp chứng nhận đủ điều kiện kinh doanh dược
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
1. Module 11 | Slide 1 of 25 2012
Basic Principles of GMP
Materials
14
2. Module 11 | Slide 2 of 25 2012
Materials
Objectives
To review specific requirements for each type of material:
Starting materials
Packaging materials
Intermediate and bulk products
Finished products
Rejected and recovered materials
Recalled products
Returned goods
Reagents and culture media
Reference standards
Waste materials
Miscellaneous materials
To examine (in groups) the problems associated with materials,
and how to overcome them
3. Module 11 | Slide 3 of 25 2012
Materials
Principle
Objective of the pharmaceutical manufacturer
produce finished products for patient's use from a
combination of materials
Materials combined
Active pharmaceutical ingredients and
Excipients (auxiliary materials)
Packaging materials
Materials include also
Gases, solvents, reagents, process aids, etc.
Special attention 14.1, 14.2
4. Module 11 | Slide 4 of 25 2012
14.3–14.6
Materials
General requirements for materials
Materials for cleaning, lubrication, and pest control
Not in direct contact with product
Suitable grade, e.g. food grade if possible
All incoming materials and finished products
quarantined after receipt or processing
– until released for use or distribution
stored
– under appropriate conditions
– orderly fashion (batch segregation)
– materials management
– stock rotation (FEFO)
Water – suitable for use
5. Module 11 | Slide 5 of 25 2012
14.7 – 14.10
Materials
Starting Materials – I
Purchasing – important operation
From approved suppliers – if possible, direct from the producer
Specifications for materials
Consignment checks
Integrity of package
Seal intact
As per purchase order
Delivery note
Supplier’s labels
Clean containers and label – ensure information readable
6. Module 11 | Slide 6 of 25 2012
14.11 – 14.14
Materials
Starting Materials – II
Report damage to containers
Separate different batches in one delivery
– sampling, testing and release
Starting materials labelled
name and internal code
Supplier's batch number(s) and manufacturer's on receipt
Status (e.g. quarantine, on test, etc.)
expiry date or retest date
Role of validated computer system
7. Module 11 | Slide 7 of 25 2012
Basic Principles of GMP
Damage to and problems
with containers
Recorded and reported
to QC
Investigated
8. Module 11 | Slide 8 of 25 2012
Materials
Examples of Labelling of Starting Materials
Name of
Material and/or
internal code
Control/
Batch No.
Status
Quarantined/Released/Rejected
(Colours may be used)
Expiry date or
retest date
Date Signature
9. Module 11 | Slide 9 of 25 2012
Basic Principles of GMP
Procedure for sampling followed - containers
labelled
10. Module 11 | Slide 10 of 25 2012
14.15 – 14.18
Materials
Starting Materials – III
Use only QC released material if within shelf-life
Dispensing
designated persons
written procedure
ensure that correct materials are accurately weighed
clean, properly labelled containers
Independent checks - recorded
material and weight or volume
Dispensed material kept together and labelled
11. Module 11 | Slide 11 of 25 2012
Basic Principles of GMP
12. Module 11 | Slide 12 of 25 2012
14.19 –14.20
Materials
Packaging materials - I
Primary and printed packaging materials
purchasing, handling and control same as for starting
materials
Printed packaging materials:
Stored in secure conditions with authorized access
Roll labels where possible in place of cut labels
Loose materials stored and transported in separate, closed
containers - to avoid mix-ups
Issued by designated personnel
SOP for issue and returns
13. Module 11 | Slide 13 of 25 2012
Basic Principles of GMP
14. Module 11 | Slide 14 of 25 2012
14.21 – 14.23
Materials
Printed and primary packaging materials - II
Each delivery or batch: specific reference number or
identification mark
Delivery to packaging department
Check quantity, identity and conformity to packaging
instructions
Outdated or obsolete material
Destroyed
Disposal record
15. Module 11 | Slide 15 of 25 2012
Basic Principles of GMP
Intermediate and bulk
products
Kept under appropriate
conditions e.g. temperature
If purchased as such
Handled on receipt as
though these are
starting materials
14.24 – 14.25
16. Module 11 | Slide 16 of 25 2012
Basic Principles of GMP
Finished products
Held in quarantine until their
final release
Then stored as usable stock
under suitable storage
conditions
Evaluation and
documentation necessary
for release
Product release procedure
Batch record review and
related procedure
14.26 – 14.27
17. Module 11 | Slide 17 of 25 2012
14.28
Materials
Rejected materials
Rejected materials and products
Clearly marked
Stored separately in restricted areas
Action – returned to supplier/destroyed, etc. in timely manner
Action approved by authorized personnel – records
maintained
18. Module 11 | Slide 18 of 25 2012
14.29 – 14.31
Materials
Rejected, reworked and recovered materials
Rework and recovery
Only in exceptional cases
– Risks involved have been evaluated and the quality of
final product will not be affected
– Specifications are met
– Defined procedure
– Records maintained
– New batch number
additional testing considered by QC
19. Module 11 | Slide 19 of 25 2012
14.32 – 14.33
Materials
Recalled products and returned goods
Recalled products
Identified
Stored separately
Secure area - access controlled
Decision taken on their fate
Returned goods
Destroyed unless suitable quality
SOP: decision regarding their fate (relabeling, resale, etc.)
– Consider: nature of product, special storage conditions,
condition, history, time elapsed since issue
Action taken to be recorded
20. Module 11 | Slide 20 of 25 2012
14.34 – 14.36
Materials
Reagents and culture media
Records for receipt or preparation
Reagents
Preparation in accordance with SOP
Appropriately labelled:
– concentration, standardization factor, shelf-life, date that
re-standardization is due, storage conditions
– signed and dated
Culture media
positive and negative controls each time prepared and used
Inoculum size appropriate
(See separate training module)
21. Module 11 | Slide 21 of 25 2012
14.37 – 14.40, 14.42
Materials
Reference standards - I
Official reference standards
Use preferable whenever these exist
Only for the purpose as per monograph
Storage conditions – see label
Reference standards prepared by the producer
Tested, released and stored in the same way as official
standards
In a secure area
A responsible person
Secondary or working standards
Appropriate checks and tests at regular intervals
Standardized against official reference standards – initially and
at regular intervals
22. Module 11 | Slide 22 of 25 2012
14.41, 14.43
Materials
Reference standards - II
Reference standards labelled with information including
Name of material
Batch, lot or control number
Date of preparation
Shelf-life
Potency
Storage conditions
Stored and used in an appropriate manner
23. Module 11 | Slide 23 of 25 2012
14.44 – 14.45
Materials
Waste materials
Waste materials
proper and safe storage when awaiting disposal
toxic substances and flammable materials:
– in suitably designed, separate, enclosed areas as per
national legislation
not to be allowed to accumulate
– collected in suitable containers for removal to collection
points
– safe and sanitary disposal
– regular and frequent intervals
24. Module 11 | Slide 24 of 25 2012
14.46
Materials
Miscellaneous materials
Miscellaneous
Rodenticides, insecticides
Fumigating agents
Sanitizing material
No contamination risk to equipment, starting
materials, packaging materials, in-process materials,
finished products
25. Module 11 | Slide 25 of 25 2012
Materials
Group session
List specific aspects of GMP requirements, in relation to the
groups of materials listed below, that you would assess when
inspecting a manufacturer
Printed packaging materials
Thermolabile materials
Water
Sterile materials
Identify three materials that present problems in your
experience
What are some of the problems that you have experienced
before and during inspection of materials?